Véronique Calleja

The Francis Crick Institute — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.2kcitations63works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(30), Protein Kinase Regulation and GTPase Signaling(19), Mechanisms of cancer metastasis(8), Cellular transport and secretion(7), Cancer, Hypoxia, and Metabolism(7)

Publications63 total

The chordoid glioma <i>PRKCA</i> D463H mutation is a kinase inactive, gain-of-function allele that induces early-onset chondrosarcoma in mice
Science Signaling·2025Open Access
Quantifying Immune Checkpoint engagement in Patient Biopsies
2025Open Access
120 Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
Regular and Young Investigator Award Abstracts·2024Open Access
259 (PB247): Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
European Journal of Cancer·2024
Abstract A124: Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (&amp;lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
Molecular Cancer Therapeutics·2023
222-G Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
Data Supplement from High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Banafshé Larijani(35), Peter J. Parker(21), Pierre Leboucher(15), Nirmal Jethwa(10), Selvaraju Veeriah(9), Julien de Naurois(9), Emma Nye(9), Tamara Bunting(9), Stefanie S. Jeffrey(9), Richard M. Stone(8), Michel S. Laguerre(7), Gordon Stamp(7), Jose Requejo‐Isidro(5), Emmanuel Van Obberghen(4), Anthony Kong(4), Adrian L. Harris(4), Juan Gumuzio(4), James Miles(4), Damien Alcor(3), Borivoj Vojnovic(3)